Home | About IJMPO | Editorial board | Search | Ahead of print | Current Issue | Archives | Instructions | Subscribe | Advertise | Contact us |  Reader Login
Indian Journal of Medical and Paediatric Oncology
Search Article 
Advanced search 
Export selected to
Reference Manager
Medlars Format
RefWorks Format
BibTex Format
  Access statistics : Table of Contents
   1995| March  | Volume 16 | Issue 1  
    Online since May 30, 2009

  Archives   Previous Issue   Next Issue   Most popular articles   Most cited articles
Hide all abstracts  Show selected abstracts  Export selected to
  Viewed PDF Cited
Neo-adjuvant/adjuvant chemotherapy in non-metastatic extremity osteosarcoma.
PVSS Sripada, SG Tenali, M Vasudevan, S Viswanathan, U Majhi, Sripada PrasadVSS
March 1995, 16(1):15-20
The aim of this study is to see the impact of neoadjuvant and adjuvant chemotherapy in non-metastatic classic osteosarcoma of the extremity, over a 5year period in our Institute. Fourty three Patients between May 1989 and May 1994 were studied. Group A numbering 15 patients received neoadjuvant chemotherapy.3 cycles preoperatively and 3 cycles of adjuvant chemotherapy after ablative surgery. The chemotherapy consisted of Ifosfamide, Adriamycin and Cisplatin in bot groups. Ther results were analysed applying Kaplan-Meier product limit method for survival and logrank test for predicting statistical significance. In Group AII(73.3 percent) patients are metastasis free with post chemotherapy grade III and IV necrosis being seen in only 4 patients(26.7 percent). In Group B 20(71.4 percent) patients are metastasis free. The 5 year survival is 76.2 percent in Group A and 60.2 percent in Group B. Neoadjuvant/adjuvant chemotherapy with Adriamycin, Cisplatin and Ifosfamide combination significantly improves the outcome in patients of non-metastatic extremity osteosarcoma and it is important to diagnose the disease early for planning preoperative chemotherapy and limb sparing surgery.\
[ABSTRACT]   Full text not available   
  665 0 -
Taxol : our experience.
AC Kapadia, CL Pai, M Gairola, J Basu
March 1995, 16(1):21-24
Taxol is one of the most important antineoplastic agents to emerge from drug screening over last decade. It has demonstrated its efficacy against ovarian, breast, lung as well as head and neck cancers, which are refractory to conventional, available chemotherapeutic agents. We have performed a pilot study with single agent Taxol in our patients with advanced, refractory stage of the disease(breast and lung cancer) to study and know more about the toxicity, efficacy and proper administration schedule. We have performed a pilot stdy with signle agent Taxol in our patients with advanced, refractory stage of the disease(breast and lung cancer) to study and know more about the toxicity, efficacy and proper administration schedule. We hope that, this knowledge gained out of our own experience will help in designing rational treatment regimens using Taxol as a single agent and in combinations.
[ABSTRACT]   Full text not available   
  641 0 -
Experience with alpha 2-B interferon at medwin cancer centre, hyderabad, india-a preliminary report.
G Sudarshan, M Babaiah, RK Sur, A Shah
March 1995, 16(1):25-31
Intron-A(Fulford India Ltd.) is an alpha 2-B Interferon and it was introduced into the Indian market 2 years ago. Our aim was to record its usefulness in various malignancies. In total 21 cases received Intron A at our centre during the last 2 years period. This included 6 cases of Chronic Myeloid Leukemia(CML- in chronic phase); 6i cases of Multiple Myeloma Stage III(MM);2 cases of Renal Cell Carcinoma with lung secondaries(RCC); 2 cases of Non-Hodgkins Lymphoma-intermediate grade-Stage II(NHL) 2 cases of Oropharyngeal carcinoma(OC); one case of Myelofibrosis(MF) and 2 cases of Advanced Breast Cancer(ACB). The cases of CML, MM and NHL are still alive and disease free after 2 years of follow up. Both the RCC cases survived more than 1 year. One of the OC cases survived for one year. The MF case died due to pneumonia. The response in breast cancer was poor. Our experience reestablishes the fact that Interon A is useful in CML, MM and NHL. Its use in solid tumors is yet to be established.
[ABSTRACT]   Full text not available   
  601 0 -
Long term sequelae of hodgkin's disease in children.
G Kapoor, H Suresh, Advani
March 1995, 16(1):8-14
Childhood Hodgkin's Disease is now accepted as a curable disease. Prolonged survival after therapy for this pediatric cancer has brought to light many late complications of therapy like gonadal failure, hypothyroidism, second malignancy, pulmonary/cardiac toxicity and fulminant sepsis. Hence choice of treatment modality is to a large extent influenced by long-term sequelae. Cure with minimal morbidity and highest quality of life achievable is now the goal of the treating physician.
[ABSTRACT]   Full text not available   
  580 0 -
Primary hodgkin's disease of bone report of a case.
MS Sandhu, BM Biswal, MC Sharma, AK Karak
March 1995, 16(1):32-35
The presentation of Hodgkin's disease as a primary solitary bone lesion is extremely rare. Survival is poor because diagnosis is often delayed and mistaken as eosinophilic granuloma. We report here a rare case of primary Hodgkin's disease of the humerus which presented as a solitary bone tumor.
[ABSTRACT]   Full text not available   
  579 0 -
Hydroxyurea in early blastic transformation of chronic myeloid leukemia.
H Agarwal, TK Tripathi
March 1995, 16(1):36-38
We report the role of hydroxyurea in tow patients of chronic myeloid leukemia in early stages of blastic transformation. Both these patients had presented in chronic phase. They attained remission by hydroxyurea and were subsequently maintained in this phase by hydroxyurea 2gm biweekly. On development of bastic transformation hydroxyurea 2gm/day ws instituted along with supportive treatment. No conventional chemotherapy was given. There was significant reduction in number of blast cells, total leucocyte counts, platelets counts with significant symptomatic relief for six to eight months.
[ABSTRACT]   Full text not available   
  570 0 -
V Naik, Naik Vibha
March 1995, 16(1):39-40
Full text not available   
  360 0 -
Current concepts in adjuvant chemotherapy.
G Kapoor, PM Parikh, SK Pai, R Gopal, SH Advani
March 1995, 16(1):2-7
Full text not available   
  258 0 -
SV Almel
March 1995, 16(1):41-42
Full text not available   
  237 0 -